| |
DME groups |
P-value* |
| SDRT |
CME |
SRD |
Combined |
All |
| Baseline CMT (µm) |
402.63±69.08 |
511.22±104.50 |
392.40±53.63 |
534.00±158.37 |
453.99±116.37 |
<0.001 |
| 3-month CMT (µm) |
278.41±55.11 |
367.06±68.09 |
334.93±63.07 |
399.56±130.06 |
336.07±92.29 |
<0.001 |
| % reduction in CMT from baseline |
29.51±15.03 |
26.59±13.25 |
15.02±7.59 |
24.42±11.84 |
24.89±13.59 |
0.008 |
| Baseline logMAR VA |
0.70±0.12 |
0.69±0.68 |
0.71±0.17 |
0.72±0.16 |
0.70±0.13 |
0.915 |
| 3-month logMAR VA |
0.49±0.11 |
0.51±0.12 |
0.57±0.13 |
0.59±0.14 |
0.53±0.13 |
0.040 |
| Improvement in logMAR VA over baseline |
-0.21±0.14 |
-0.18±0.12 |
-0.14±0.15 |
-0.13±0.18 |
-0.17±0.15 |
0.319 |
|
| DME: Diabetic Macular Edema; SDRT:Diffuse Retinal Thickening; CME:Cystoid Macular Edema Pattern; SRD: Serous Retinal Detachment; Combined: Combination of CME and SRD; CMT: Central Macular Thickness; logMAR: logarithm of the Minimum Angle of Resolution; VA: best-corrected visual acuity; Reduction ratio is calculated as the baseline CMT-3 month CMT/baseline CMT.Values shown are the mean ± standard deviation. *Kruskal-Wallis test (among DME groups). |
| Table 2: Central macular thickness and visual acuity at baseline and 3 months after intravitreal bevacizumab. |
